General Information

Continuum 2024

For the past 18 years, IAPAC has proudly served as the secretariat for the annual series of International Conferences on HIV Treatment and Prevention Adherence, otherwise known as Adherence. Over the past few years, and as our understanding of gaps across the HIV care continuum has been refined, the conference has undergone an evolution with an expanded scope reflecting a more holistic approach to addressing gaps across the entire HIV care continuum. This evolution led us to redefine the conference for its 19th iteration, including a name change to “Continuum 2024.”

The new name embodies our commitment to encompass the entire journey of people affected by HIV, from the critical initial step of testing, through linkage to care, active engagement in prevention and treatment services, adherence to prevention and treatment regimens, and re-engagement for those who are lost to follow-up. By choosing “Continuum” as our conference title, we aim to emphasize the importance of viewing HIV care as a journey where every step along the way holds immense significance, while continuing to highlight innovations to optimize HIV treatment and prevention adherence.

Continuum 2024 aims to continue the conference tradition of serving as a platform that unites providers, researchers, policymakers, and advocates to share insights, best practices, and innovative approaches that contribute to an optimized continuum of HIV care. Through this collective effort, we aspire to drive positive change and ultimately progress towards a world where HIV care is seamlessly accessible, efficient, and inclusive, ensuring a better quality of life for all affected communities.

CONFERENCE INFORMATION 

The Continuum 2024 conference will take place June 9-11, 2024, at El Conquistador in Puerto Rico. Hosted by the International Association of Providers of AIDS Care (IAPAC), this annual series of conferences features the presentation and discussion of HIV treatment and biomedical prevention adherence research, and current behavioral and clinical perspectives in practicum, within the context of optimizing the continuum of HIV care and prevention.

Under the theme of Breaking Barriers, Bridging Gaps, the conference will feature a Keynote Address, Memorial Lecture, Memorial Colloquium, five thematic sessions, oral abstracts sessions, and an e-poster abstracts session.

Co-chaired by Kenneth K. Ngure (Jomo Kenyatta University, Nairobi, Kenya) and Carmen Zorrilla (University of Puerto Rico, San Juan, PR), the conference will focus on innovations to optimize the continuum of HIV care, leveraging implementation science to bridge HIV continuum gaps, promoting community-led HIV research and programming, and addressing social determinants of health. Through these focus areas the conference aims to:

  • Focus on strategies and interventions to enhance the entire HIV care continuum
  • Explore advances, strategies, and best practices in delivering combination HIV prevention
  • Address real-world integration of evidence-based practices through implementation science
  • Propose strategies to translate research findings into scalable interventions for impact
  • Highlight community-led approaches and initiatives to shape effective HIV responses
  • Discuss interventions, policies, and strategies to address social determinants of health

A downloadable PDF version of the Continuum 2024 conference program may be viewed here.

ACCREDITATION 

Continuum 2024 is accredited for physicians, nurses, pharmacists, PA, psychologists, social workers, and interprofessional health workers. Please see the full accreditation statements below.

Target Audience

The target audience for the Continuum 2024 conference includes physicians, nurses and nurse-practitioners, pharmacists, psychologists, behavioral scientists, social scientists, public health specialists, epidemiologists, social workers, case managers, peer educators and navigators, and community health workers working in the field of HIV medicine. Because the conference outcomes are intended to influence public policy around global, national, and municipal HIV responses, the conference may also be of interest to policymakers and individuals who wish to advocate as well as enact and implement evidence-informed HIV policies and interventions in their respective communities and countries.

Educational Objectives

Upon successful completion of this activity, learners will be able to:

  1. Employ strategies to improve antiretroviral therapy and pre-exposure prophylaxis outcomes
  2. Utilize implementation science to identify high impact and scalable HIV interventions
  3. Facilitate community engagement in clinical care to support optimal HIV service delivery
  4. Address social determinants of health to enhance HIV responses and outcomes

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and IAPAC.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Education

PACE designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 13.25 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 13.25 contact hour(s) (0.13.25 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number – JA4008073-9999-24-011-L02-P)

Type of Activity: Knowledge

PA Continuing Medical Education

 

PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Credit Designation

This program offers 13.25 continuing education credits for psychologists.

Social Work Continuing Education

As a Jointly Accredited Organization, Partners for Advancing Clinical Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 13.25 Clinical continuing education credits.

 

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 13.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

REGISTRATION

Following are key dates for early and standard conference registration, as well as registration rates:

Deadline Dec. 1, 2023 Mar. 7, 2024 April 26, 2024 N/A
Registration Type Early-Bird Early Standard Late/Onsite
Member (must be current) $225 $275 $325 $375
Non-Member $250 $300 $350 $400
Student or Retired $175 $200 $225 $275
One-Day Only $125 $150 $200 $250

NOTE: Registration fee payments must be received on or prior to the deadline for a specific registration type (Early-Bird, Early, or Standard). If payment of a registration fee is not received by the stated deadline, the next higher category of registration fee will be applied/required to attend the conference. Prompt payment of registration fees based on the deadline schedule is encouraged.

Cancellations, Refunds, and Transfers

Registrations may be cancelled and refunded (minus a $100 cancellation fee) through April 26, 2024. Requests received after this date will not be eligible for a refund. Registration payments may be transferred to another attendee in the event that you are no longer able to attend the conference. There are no fees associated with registration transfers. Please send all registration cancellation and transfer requests to events@ftcinstitute.org.

ABSTRACT SUBMISSION

Following are key dates for abstract submission (with additional information and guidance available by clicking the Abstracts tab on this webpage):

Abstract Submission/Disposition

  • Abstract Submission Portal Open – Dec. 1, 2023
  • Abstract Submission Deadline – Feb. 16, 2024
  • Late-Breaker Abstract Submissions – March 25-29, 2024
  • Abstract Disposition Announcements – March 22, 2024
  • Late-Breaker Disposition Announcements – April 19, 2024
  • Deadline to Withdraw Abstract/Change Presenting Author – May 3, 2024

HOTEL ACCOMMODATIONS

IAPAC has negotiated a discounted room block for conference attendees. Accommodations are available on a first-come, first-served basis. Book your room today to ensure you secure accommodations at the official conference hotel.

Select the “Venue” tab above to access the room reservation link.

EXHIBITOR AND SPONSORSHIP INFORMATION

The Continuum 2024 conference provides an opportunity to interact with more than 400 delegates, in-person, from a variety of practice settings and experiences, including physicians, nurses, pharmacists, psychologists, social workers, community health workers, and patient advocates. There are a limited number of sponsorship opportunities available for this conference.

View the Continuum 2024 Sponsorship Prospectus here.

Please contact IAPAC’s Senior Director of Education, Jonathon Hess, at jhess@iapac.org if your organization has an interest in hosting a satellite symposium or with any sponsorship-related queries.

ACKNOWLEDGEMENT 

The Continuum 2024 conference is made possible through educational grants, corporate sponsorships, and individual registration and exhibitor fees. We acknowledge education grants from Gilead Sciences and Merck & Co. and a corporate sponsorship from ViiV Healthcare.

Schedule

Sunday, June 9, 2024

TimeSessionRoom
PRE-CONFERENCE SESSION
9:00 AM – 10:30 AMRethinking Acceptability in HIV Care and Prevention
Hosted by Weill Cornell Medicine
Panelists:
Cory Bradley (Northwestern Medicine, Chicago, IL, USA)
Whitney Irie (Boston College School of Social Work, Boston, MA, USA)
Radhika Sundararajan (Weill Cornell Medicine, New York, NY, USA)
10:30 AM - 12:00 PMFireside Chat with Global HIV Leaders:
Ending AIDS as a Public Health Threat by 2030 and Beyond
Hosted by UNAIDS and IAPAC
Moderator:
José M. Zuniga (IAPAC and FTCI, Tampa, FL, USA)
Panelists:
Angeli Achrekar (Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland)
Meg Doherty (World Health Organization, Geneva, Switzerland)
Yogan Pillay (Bill & Melinda Gates Foundation, Johannesburg, South Africa)
1:00 PM – 1:15 PMWELCOME REMARKSGENERAL SESSION
Welcome to Continuum 2024

Kenneth K. Ngure (Jomo Kenyatta University, Nairobi, Kenya)
Carmen Zorrilla (University of Puerto Rico, San Juan, PR)
José M. Zuniga (IAPAC, Tampa, FL, USA)
1:15 PM – 1:45 PMKEYNOTE ADDRESSGENERAL SESSION
Innovation as Catalyst: Paving a Path to HIV Epidemic Control

Yogan Pillay (Bill & Melinda Gates Foundation, Pretoria, South Africa)
1:50 PM – 3:05 PMHIV CARE CONTINUUM

Moderator: Julie Levison (Harvard Medical School, Boston, MA, USA)
GENERAL SESSION
HIV Prevention Innovations: Beyond Traditional Approaches
Mariano Kanamori (University of Miami, Miami, FL, USA)
Engaging and Re-Engaging in HIV Care: Strategies for Success
Tom Giordano (Baylor College of Medicine, Houston, TX, USA)
HIV Care Continuum Optimization: Leveraging Technology
Julian Adong (Mbarara University of Science & Technology, Mbarara, Uganda)
3:10 PM – 4:25 PMIMPLEMENTATION SCIENCE

Moderator: Stefan Baral (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA)
GENERAL SESSION
Bridging Gaps: Community-Based Strategies for PrEP Scale-Up
Maggie Chase (USAID, Washington, DC, USA)
Trauma-Informed: Healing Pathways to Enhance HIV Services
Tiara Willie (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA)
Beyond Barriers: Enhancing the Reach of HIV Service Delivery
Thomas Odeny (Kenya Medical Research Institute, Nairobi, Kenya)
4:30 PM – 5:30 PMTHREE TOP-RATED ABSTRACTSGENERAL SESSION
5:30 PMADJOURN

Monday, June 10, 2024

TimeSessionRoom
8:00 AM – 9:00 AMSPONSORED SATELLITE SYMPOSIUM
PrEP Today: Data Discussions on an HIV-1 PrEP Option
Sponsored by ViiV Healthcare
9:00 AM – 9:30 AMGARY S. REITER AND ANDREW KAPLAN MEMORIAL LECTUREGENERAL SESSION
Person-Centered HIV Care: Lessons from the Frontlines

Meg Doherty (World Health Organization, Geneva, Switzerland)
9:35 AM – 10:50 AMHIV TREATMENT

Moderator:
Vanessa Apea (Barts NHS Trust, London, England, UK)
GENERAL SESSION
Innovative Frontiers: Long-Acting ART for Maximum Impact
Christoph Spinner (University Hospital Rechts der Isar, Munich, Germany)
Intersectionality in ART Utilization: A Comprehensive Approach
Zandraetta Tims Cook (Emory University School of Medicine, Atlanta, GA, USA)
Future Horizons: Innovations Shaping the ART Landscape
Moti Ramgopal (Midway Immunology and Research Center, Fort Pierce, FL, USA)
10:50 AM – 11:00 AMBreak
11:00 AM – 12:00 PMORAL ABSTRACTS SESSIONS 1

1014 Social Determinants of Health Predict HIV Prevention and Care Continua Status among Sexual Minority Men Who Use Methamphetamine

Brandon Knettel (Duke University, Durham, NC, USA)

1077Development and Fidelity Testing of a Brief Suicide Prevention Intervention for People Living with HIV in Kilimanjaro, Tanzania
Cathy Reback(Friends Research Institute / UCLA, Los Angeles, CA, USA)

1098 Implications of PrEP Prescribing Practices on Patient Retention and On-Time Prescriptions

Sarit Golub (Hunter College and Graduate Center of the CIty University of New York, New York, NY, USA)

1136 Combing HIV Prevention Options with Mental Health Service Delivery for Adolescent Girls (CHOMA): Results of a Pilot Hybrid Effectiveness-Implementation Randomized Trial

Jennifer Velloza (University of California, San Francisco, San Francisco, CA, USA)

11173 What Matters Most for Long-Acting Antiretroviral Therapy? A Discrete Choice Experiment
Rebecca Fisk-Hoffman (University of Florida, Gainesville, FL, USA)

1202 Acceptability and Usefulness of a Relational Agent-Based Mobile Phone App Promoting Healthy Behaviors in Young Black MSM with HIV

Sierra Upton (University of Illinois at Chicago, Chicago, IL , USA)

1203 Screening for Violence Exposures in a Trauma-Informed Manner: Identifying an Optimal Screener for HIV Care Settings
Jessica Sales (Emory University, Rollins School of Public Health, Atlanta, GA, USA)

1206 A Pilot Randomized Control Trial of Motivational Interviewing to Increase PrEP Uptake (MI-PrEP) among Black Women Placed at Risk for HIV in the U.S.
Sannisha Dale (Miami, Durham, FL, USA)

1207 Early Implementation Experience and Lessons Learned from Eight Diverse Clinics Introducing Long-acting Injectables for HIV Treatment

Kathrine Meyers (Aaron Diamond AIDS Research Center at Columbia University, New York, NY, USA)

1014 Development and Fidelity Testing of a Brief Suicide Prevention Intervention for People Living with HIV in Kilimanjaro, Tanzania
Brandon Knettel (Duke University, Durham, NC, USA)

1208 Outcomes of Rapid Antiretroviral Therapy (ART) Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco

Jorge Salazar (University of California, San Francisco, an Francisco, CA, USA)

1210 Substantial Missingness of Electronic Adherence Monitoring Data in a Randomized Clinical Trial (RCT) of Young Black MSM
Kara Herrera (University of Illinois at Chicago, IL, USA)

1212 Early Implementation and Clinical Outcomes from Real-World Use of Injectable Cabotegravir/Rilpilvarine (iCAB/RPV) at Eight US Clinics Participating in the ALAI UP Project

Nadia Nguyen (Aaron Diamond AIDS Research Center at Columbia University, New York, NY, USA)

1213 Using Electronic Health Records Data to Identify Incarcerated Persons at Increased Risk for HIV Acquisition

Alex Treacher (Parkland Center for Clinical Innovation, Dallas, Texas, USA)

1257 Clinician Perspectives on U=U and Zero HIV Transmission Risk

José Zuniga (IAPAC, Tampa, Florida, USA)

1258 Moving Beyond Viral Suppression: Poor Patient-Provider Communication and Its Impact on Overall Health Management Among People Living With HIV in the United States

José Zuniga (IAPAC, Tampa, Florida, USA)

1266 Who Could Benefit From Long-Acting Injectable Antiretroviral Therapy? A Qualitative Study Among Florida Providers and People with HIV

AbigailGracy (University of Florida, Gainesville, Florida, USA)

1291 Understanding the Treatment Experience: A Qualitative Study of Patient Living with HIV who Transitioned from Oral Antiretrovirals to Cabotegravir/Rilpivirine Injectable Therapy.

RobertVelez (Nova Southeastern University, San Juan, Puerto Rico, USA)

1310 Implementers’ Perspectives and Modifications to Implementation Strategies Used to Increase PrEP Initiation and Persistence Among Cis-Gender Adolescent Girls and Young Women and Female Sex Workers in South Africa: A Sequential Explanatory Mixed Methods Study

WilsonGomez (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

2016 High retention among Black, Latinx, Transgender LAI CAB PrEP users in a peer CHW-led program within a primary care center in Washington, D.C.

Juan Carlos Loubriel (Whitman-Walker Health, Washington, DC, USA)
BREAKOUT ROOMS
12:00 PM – 12:15 PMBreak
12:15 PM – 1:30 PMLUNCH SYMPOSIUM
Sponsored by ViiV Healthcare
GENERAL SESSION
1:30 PM – 1:45 PMBreak
1:45 PM – 2:45 PME-POSTER SESSIONFOYER
2:45 PM – 3:00 PMBreak
3:00 PM – 4:00 PMORAL ABSTRACTS SESSIONS 2

1018 Effects of a Rideshare Intervention on HIV Care Engagement in South Carolina

Sayward Harrison (University of South Carolina, Columbia, SC, USA)

1097 PrEP Up Pharmacies: Preliminary Evidence of a Pharmacy-Based Same-Day Pre-Exposure Prophylaxis (PrEP) Screening and Dispensing Model in the United States Southeast

Natalie Crawford (Emory University, Atlanta, GA, USA)

1099 Towards Rapid Dapivirine Measurement with a Portable, Low-Cost Platform

Cara Brainerd (University of Washington, Seattle, WA, USA)

1117 Impact of a Harm Reduction Program Tailored for Priority Populations who Use Methamphetamine in New York City (NYC)

Justin Knox (Columbia University, New York City, NY, USA)

1121 Utilizing a Stepped Care Approach to Address Substance Use and Increase PrEP Initiation and Adherence among Trans Women and Sexual Minority Men

Cathy Reback (Friends Research Institute / UCLA, Los Angeles, CA, USA)

1126 Impact of Peer Referral on Pre-Exposure Prophylaxis Adherence and Persistence among Gay, Bisexual, and Other Men Who Have Sex with Men: A Cohort study in China

Weiming Tang (University of North Carolina at Chapel Hill, Chapel Hill, NC, USA)

1183 New HIV Diagnoses and Community Viral Load During the COVID-19 Pandemic in Washington, DC

Amanda Castel (George Washington University Milken Institute School of Public Health, Washington, DC, USA)

1200 Engagement with an Interactive Adherence Text Messaging Platform among Women Initiating PrEP during Pregnancy in Kenya: The Mobile WACh-PrEP Study

Salphine Watoyi (Kenyatta National Hospital, Kisumu, Kenya)

1237 Assessment of Catastrophic Health Expenditure Among Households in Kogi State, North Central Nigeria

Moses Luke (AIDS Healthcare Foundation, Lokoja, Nigeria)

1270 HIV Care Continuum Outcomes in a Cohort of Transgender Women in the United States

Erin Cooney (Johns Hopkins University, Baltimore, MD, USA)

1303 Initial Clinical Care Experiences of Men Who Have Sex with Men and Transgender Men who Choose Injectable PrEP in the United States: Results from the PILLAR Study

Heidi Swygard (ViiV Healthcare, Durham, NC, USA)

1320 Pilot Demonstration Project of a Client-Provider Communication Tool to Facilitate PrEP Awareness and Uptake among Black/African American Cisgender Women in the US South

Victoria McDonald (University of Alabama at Birmingham, Birmingham, Alabama, USA)

1324 Personnel Identified Barriers and Facilitators to Implementing Trauma-Informed HIV Care for Youth in Southern US

Megan Wilkins (St. Jude Children's Research Hospital, Memphis, TN, USA)

1335 Challenges and Opportunities to Optimize HIV Responses in US Fast-Track Cities

Dashiell Sears (Fast-Track Cities Institute, Washington, DC, USA)
BREAKOUT ROOMS
4:00 PM – 4:15 PMBreak
4:15 PM – 5:30 PMHIV PREVENTION

Moderator:
Rupa Patel (US CDC, Atlanta, GA, USA)
GENERAL SESSION
Enhanced Outreach: Data-Driven, Equity-Based PrEP Scale-Up
Sten Vermund (Yale School of Public Health, New Haven, CT, USA)
Optimized Access: Differentiated Service Delivery for Rapid PrEP
Elzette Rousseau (Desmond Tutu Health Foundation, Cape Town, South Africa)
Building Bridges: Multisector Engagement to Increase Long-Acting PrEP Use
Albert Liu (UCSF-Bay Area CFAR, San Francisco, CA, USA)
5:45 PM – 6:45 PMSPONSORED SATELLITE SYMPOSIUM
Treating Virologically Suppressed Patients: Key Study Data
Sponsored by ViiV Healthcare
Tulika Singh (UCI Health, Palm Springs, CA, USA)

Tuesday, June 11, 2024

TimeSessionRoom
8:00 AM – 8:45 AMSPONSORED SATELLITE SYMPOSIUM
Transforming HIV Specialty Care Leveraging Retail Pharmacy

Sponsored by Walmart
BREAKOUT ROOM
Presenters:
Aleata Postell (Walmart, Bentonville, AR, USA)
Kathryn Harris (Walmart Specialty Pharmacy, Orlando, FL, USA)
9:00 AM – 9:45 AMMARIO S. COOPER MEMORIAL COLLOQUIUM GENERAL SESSION
Policy Advocacy for PrEP Access: Lessons from the Field
Moderator:
Damián Cabrera-Candelaria (NMAC, San Juan, PR)
Panelists:
Noelle Esquire (Elton John AIDS Foundation, Wilmington, NC, USA)
Jeremiah Johnson (PrEP4All, New York, NY, USA)
9:50 AM – 11:05 AMSOCIAL DETERMINANTS OF HEALTH

Moderator:
Richard Chilongosi (Family Health Services, Blantyre, Malawi)
GENERAL SESSION
Data-Driven: Geolocating Economic, Food, and Housing Insecurity
Ana Penman-Aguilar (US CDC, Atlanta, GA, USA)
Progress Metrics: Evaluating Social Determinants Interventions
Community-Centered Health: Scaling Up Grassroots Innovation and Building Ecosystems
Karina Maldonado-Mariscal (TU Dortmund University, Dortmund, Germany)
11:05 AM – 11:15 AMBreak
11:15 AM – 12:15 PMORAL ABSTRACTS SESSIONS 3

1009 Trauma-resilient Research Co-Production in Southern HIV Care Organizations

Lauren Brown (Meharry Medical College, Nashville, Tennessee, USA)

1016 Men Interrupted: Strategies to reduce high rates of treatment interruptions among men who have sex with men (MSM) in South Africa

Dorian Gule (OUT LGBT Well-Being, Johannesburg, South Africa)

1021 The Association Between Support Services and Linkage to HIV Care Among Persons Newly Diagnosed with HIV by Homelessness and Unstable Housing (HUH)

Jonny Andia (Centers for Disease Control and Prevention, Atlanta, GA, USA)

1032 Improving HIV Viral Load Coverage through Strategic Facility-level Interventions: Best Practices from the USAID-DISCOVER-Health Project

Musonda Musonda (USAID, Lusaka, , Zambia)

1033 Pregnant, Young and at High(er) Risk of HIV infection: Suboptimal Pre-exposure Prophylaxis Continuation in Pregnant Adolescent Girls and Young Women in Primary level Facilities in Zambia

Musonda Musonda (USAID, Lusaka, Zambia)

1065 HIV Incidence Following Pre-Exposure Prophylaxis (PrEP) Initiation Among Key Populations in Resource-Limited Setting: Insights from Indonesia

Nadia Hanum (Bandung Institute of Technology, Bandung, Indonesdia)

1075 Addressing Treatment Interruption among people living with HIV using a systematic monitoring tool piloted in Bacoor City, Philippines

Maria Michella Rabara (EpiC HIV - FHI 360, Makati, Philippines)

1102 National HIV/AIDS Strategy Indicators for HIV Stigma and Quality of Life among People Living with HIV who Inject Drugs in the United States, 2017-2021

Christine Mattson (CDC, Atlanta, GA, USA)

1132 Opportunities and Challenges in Reaching Adolescents and Young Adults with PrEP through School Based Health Centers

Kathrine Meyers (Columbia University Irving Medical Center, New York, NY USA)

1157 An Exploration of the Cumulative Effects of Trauma and LGBTQ+-Related Violence on the Mental Health of Black and Latino Sexual Minority Men At-Risk for or Living With HIV

Orlando Harris (University of California, San Francisco, School of Nursing, San Francisco, CA, USA)

1170 PrEP Receipt versus PrEP Use among Adolescent Girls and Young Women Offered Peer-Delivered, Community-Based Services in Kisumu, Kenya

Lawrence Juma (Kenya Medical Research Institute, Kisimu, , Kenya)

1204 Strategies for Success: Enhancing Viral Load Suppression among Women with HIV in Puerto Rico

Carmen D. Zorrilla (University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico)

1227 Demographic and Behavioral Correlates of PrEP Uptake and Discontinuation Among English and Spanish-Speaking Transgender Women in New York City: The TURNNT Cohort Study

Alexander Furuya (Columbia University, New York City, NY, USA)

1269 Improving Optimization of Pediatrics Antiretroviral Doses through Mentorship in Kogi State, Nigeria.

Idowu Orogbemi (AIDS HealthCare Foundation, Lokoja, Nigeria)

1293 Creating Human Rights Networks to Reduce Rights Violations and Improve Quality of Life for Key and Vulnerable Populations in Honduras

Joseph Amon (Drexel University, Philadelphia, PA, USA)
BREAKOUT ROOMS
12:15 PM – 12:30 PMBreak
12:30 PM – 1:45 PMLUNCH SYMPOSIUM
Addressing Critiques of HIV-Related Stigma and Discrimination Measurement: Moving the Science Upstream

Sponsored by NIMH and NIH OAR and Hosted by IAPAC
GENERAL SESSION
1:45 PM – 2:00 PMBreak
2:00 PM – 3:00 PMORAL ABSTRACTS SESSIONS 4

1003 The Other Half: Integrating Qualitative Analyses Across Three Cohorts of Black and Latino Persons Living with HIV Who Are Not HIV Virally Suppressed

Marya Gwadz (New York University, New York, NY, USA)

1030 Effectiveness of Data-to-Care Activities for Improving HIV Care Outcomes: A Systematic Review

Kristin Roberts (Centers for Disease Control and Prevention, Lilburn, GA, USA)

1078 Medicaid Insurance Expansion and its Association with HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study.

Emmanuel Nazaire Essam Nkodo (University of Nebraska Medical Center, Omaha, NE, USA)

1092 Anti-Stigmatizing, Client-Centered Sexual History as an Effective Implementation Strategy to Increase EHE Intervention Delivery in Diverse Clinical Settings

Sarit Golub (Hunter College and Graduate Center of the CIty University of New York, New York, New York, USA)

1110 Contextual Factors Influencing Implementation of HIV Treatment Support Strategies for Female Sex Workers Living with HIV in South Africa: A Qualitative Analysis Using The Consolidated Framework for Implementation Research

Carly Comins (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

1112 Implementing Complex HIV Treatment Support Strategies for Female Sex Workers Living with HIV: a Realist-informed Evaluation

Carly Comins (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

1146 Geographic Variations in Real-World Uptake of Oral Pre-Exposure Prophylaxis Prescription Claims in ‘Ending the HIV Epidemic in the United States’ Regions

Li Tao (Gilead Sciences, Foster City, CA, USA)

1153 Best Practices Learned from PEPFAR HRSA Skills Sharing Program in Jamaica

Lauren Richey (Louisiana State University Health Sciences Center, New Orleans, LA, USA)

1196 Socio-contextual Influences on Time to Viral Suppression in the Deep South: A Qualitative Analysis

D. Scott Batey (Tulane University, New Orleans, Louisiana, USA)

1199 Misclassification of HIV Care Outcomes in a Population-Representative Sample of People Living with HIV in KwaZulu-Natal Province, South Africa

Lindsey Filiatreau (Washington University in St. Louis, St. Louis, MO, USA)

1308 Predictors of Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda Through 48 Weeks of Follow-Up

Cameron Nutt (Mass General Brigham, Boston, Massachusetts, USA)

1315 The Association Between Antiretroviral (ARV) Medication Adherence and Composite Medication Adherence for Non-HIV Chronic Conditions in People with HIV (PWH)

Michael Miller (Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA)

1321 Modeling Longitudinal Trajectories of Antiretroviral (ARV) Medication Adherence and Composite Medication Adherence for Non-HIV Chronic Conditions in People with HIV (PWH)

Michael Miller (Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA)

1337 Divergent Perspectives about the Scientific Underpinnings of U=U among PLHIV and HIV-Negative Individuals

Kalvin Pugh (IAPAC, Kansas City, KS, USA)
BREAKOUT ROOMS
3:00 PM – 3:30 PMHIGHLIGHTS FROM CONTINUUM 2024GENERAL SESSION
3:30 PM – 4:00 PMCLOSING REMARKSGENERAL SESSION
Kenneth K. Ngure (Jomo Kenyatta University, Nairobi, Kenya)
Carmen Zorrilla (University of Puerto Rico, San Juan, PR)
José M. Zuniga (IAPAC, Tampa, FL, USA)
4:00 PMADJOURN

Register

Venue and Accommodations

The Continuum 2024 conference venue will be El Conquistador, which is located at 1000 Avenida El Conquistador, Fajardo, 00738, Puerto Rico. IAPAC has negotiated a discounted group rate for conference attendees available on a first-come, first-served basis. Rooms are currently sold out for the discounted rated, but rooms may open up as cancellations occur. You may also book directly with the hotel or through a travel agency at the standard hotel rate.

NOTE: The conference is taking place in the city of Fajardo, not San Juan. Fajardo is a 35- to 40-minute commute from the San Juan International Airport (SJU). Transportation service to the venue may be arranged by clicking here. Alternatively, you may opt to order a taxi at the taxi stand at SJU airport or by using a rideshare app.

Check availability of discounted accommodations here.

ACCOMMODATIONS OUTSIDE OF THE CONFERENCE HOTEL

IAPAC has negotiated a second discounted group rate for conference attendees at the Fairfield by Marriott Luquillo Beach available on a first-come, first-served basis. Rooms are available from June 5, 2024 through June 13, 2024 at a room rate of $189 + $25 resort fee per night + 11% local tax. This hotel is about 20-minutes using rideshare or taxi service from El Conquistador, the Continuum 2024 conference venue.

Book your accommodations at the Fairfield by Marriott here.

Another option for accommodations that is 10-15 minutes walking along the waterfront to El Conquistador, the Continuum 2024 venue, is the Sueños del Mar. IAPAC does not have a group rate with this hotel, but attendees looking for affordable accommodations within walking distance to the venue may enquire by visiting the hotel’s website. https://suenosdelmar.info/ 

Submit an Abstract

Abstract Presenter Resources

Oral abstract presenter FAQ


The Continuum 2024 conference will feature oral abstract and e-poster sessions. Below is abstract submission guidance to inform domain selection, abstract authorship, and online submission.

KEY DATES

Following are key dates relevant to abstract submissions:

  • Abstract Submission Deadline – Feb. 16, 2024
  • Late-Breaker Abstract Submissions – March 25-29, 2024
  • Abstract Disposition Announcements – March 22, 2024
  • Late-Breaker Disposition Announcements – April 19, 2024
  • Deadline to Withdraw Abstract/Change Presenting Author – May 3, 2023

 

CALL FOR ABSTRACTS

Abstract submissions are encouraged in a wide variety of specific domains, including:

  • ART initiation/adherence
  • Behavioral dynamics
  • Biomedical prevention
  • Community engagement
  • Community research
  • Cultural competence
  • Digital health/analytics
  • Engagement, re-engagement
  • Harm/risk reduction
  • Health equity in HIV care
  • Health policy/financing
  • Health-related QoL
  • Implementation science
  • Legal/ethical dimensions
  • Peer support/navigation
  • PrEP initiation/persistence
  • Prevention continuum
  • Psychosocial support
  • Social determinants of health

 

Within these areas we encourage coverage of:

  • Advances in basic science
  • Longitudinal or observational data
  • Innovations in modeling and biopsychosocial theory
  • Intervention development, implementation, and/or outcomes
  • Dissemination/implementation of evidence-based approaches
  • Operations research, demonstration projects, and practice-based approaches
  • Resource, structural, and service delivery issues and innovations
  • Implementation science design, evidence, and real-world applicability

 

Particularly as applied to key and disproportionately affected populations and settings:

  • Treatment naïve, treatment experienced
  • Individuals living with mental and/or physical health challenges
  • Concomitant diseases (e.g., HBV, HCV, TB)
  • Comorbid conditions (e.g., diabetes, hypertension)
  • Syndemic conditions (e.g., mental health, substance use)
  • Resource-constrained settings and geographies
  • Key and vulnerable populations:
    • Men who have sex with men (MSM)
    • Transgender individuals
    • Gender non-conforming
    • Women in high HIV incidence areas
    • Female and male sex workers
    • Pregnant women
    • Children and adolescents
    • Substance users
    • Incarcerated or recently released individuals
    • Homeless and/or marginally housed individual

 

ABSTRACT SUBMISSION

Abstracts must be submitted online by 5 pm ET, Feb. 16, 2024. Submitted abstracts will be considered for oral or e-poster presentation. Submitted abstracts should report information not previously published, or intended to be published, prior to May 3, 2024.

It is the responsibility of the presenting author to ensure accuracy of content, spelling, and presentation. Abstracts will be published as submitted, subject to reformatting that may be required by IAPAC.

ABSTRACT FORMAT

Abstract contents will be either research-based data using established scientific methods or demonstrate experience and information from individuals or institutions working in the field. Please follow one of two structured formats (A or B), indicating in bold the four parts of your abstract:

Format A: Data-Driven Abstracts

  1. Background: a concise statement of the issues evaluated
  2. Methods: the investigational model used
  3. Results: specific findings
  4. Conclusions: summary of findings, supported by results

Format B: Program Descriptions and Case Studies

  1. Introduction: a concise statement of the issues addressed
  2. Description: a description of the project, case study, experience, or intervention
  3. Lessons Learned: project results, implementation issues, and/or case study solutions
  4. Recommendations: further recommendations or next steps

GENERAL GUIDELINES

Following are some general guidelines for individuals interested in submitting an abstract(s):

  • The abstract must NOT contain more than 300 words.
  • Acceptable abstracts shall contain a concise statement of the research, define the precise subject of the presentation, and be related to the main theme or a sub-theme of the conference.
  • Literature references and acknowledgements should not form any part of the abstract’s content.
  • Figures and tables are acceptable, subject to high definition/quality guidance to be provided.
  • The author is responsible for grammatical and factual details and may edit an abstract after it has been submitted up to May 3, 2024.
  • All abstracts must be submitted in English (without exception).
  • Sub-specialty jargon should be avoided, reflecting the interdisciplinary nature of the conference.
  • Define all abbreviations and concepts in your abstract at first use.
  • For therapeutic agents, only generic names may be used (trade names are not permitted).

 

ABSTRACT SUBMISSION AND ACCEPTANCE

All abstracts must be submitted online no later than 5:00 pm ET, February 16, 2024. Submissions will be acknowledged upon successful submission via the site. Faxed or mailed abstracts will not be considered.

Please record your abstract number. The number assigned to your abstract when it is submitted online will be the abstract number referenced throughout the conference, including in the Program and Abstracts book, during the Oral Abstract sessions, and during the e-Poster Session. A notice of acceptance or rejection will be sent via e-mail no later than March 22, 2024. A notice of acceptance or rejection for late-breaker submissions will be sent via e-mail no later than April 19, 2024. The disposition of each abstract will be sent via e-mail only to the submitting author identified on the submission form for that abstract. That contact will be responsible for sharing the disposition with all other authors of the abstract (including the presenting author).

Accepted abstracts will be in one of two categories:

  1. Oral Abstract presentation
  2. e-Poster Abstract presentation

 

Presenting authors agree to register for and attend the conference as scheduled in either Oral Abstract sessions or the e-Poster Session. Oral abstract and e-poster presenters are responsible for their own travel and accommodation expenses, as well as the applicable registration fees.

Note that only the abstracts of paid conference registrants will be included in the final Abstracts Book. Accepted abstracts will be published in the conference proceedings. Abstracts are considered official communication to IAPAC. Submission of an abstract implies permission to publish abstracts (including in the Journal of the International Association of Providers of AIDS Care [JIAPAC]) and online posting, if accepted. E-posters files must be transferred to IAPAC by June 2, 2023.

To reiterate, all abstract submissions must be received online by 5:00 pm ET, February 16, 2024. It is strongly recommended that you do not wait until the last minute to submit your abstract(s). You may review/edit submissions from now until 5:00 pm ET, May 3, 2024. Abstracts may be withdrawn, or the presenter may be changed, until May 3, 2024.

For frequently asked questions about abstracts submissions, please visit the conference FAQ by selecting the tab above.

Awards

IAPAC “Rising Star” Award for an Early-Career HIV Researcher

IAPAC would like to recognize an early career researcher (i.e., within 10 years of their terminal degree) who has already demonstrated expertise and impact in any aspect of HIV research. The recipient will be chosen based on their potential to move the field forward in new and exciting directions.

IAPAC Outstanding Contribution to HIV Care Continuum Award for a Senior Researcher

IAPAC would like to recognize a senior researcher (i.e., more than 10 years after their terminal degree) who has significantly contributed to the field of HIV care continuum, with evidence of scientific impact. The recipient’s mentorship of other investigators also will be considered in determining the awardee.

Please nominate yourself or another by completing the linked form by May 3, 2024.

Please note, the following attachments will be requested for upload in the form for submission.

  • Biosketch
    • Figures, tables, or graphics are not allowed in the biosketch. Do not embed or attach files (e.g. video, graphics, sound, data).
    • The biosketch may not exceed  5 pages per person.
  • One letter (max 1 page) describing the nominee’s impact on the field of HIV adherence research; more than one person may contribute to the letter

FAQ

When and where will Continuum 2024 take place?

The Continuum 2024 conference will take place June 9-11, 2024, at El Conquistador in Fajardo, Puerto Rico. Click here to access the conference program. Note: there is not a virtual component to this conference.

What is included in my conference registration?

Standard registration includes 3-day access to the conference. One day registration includes 1-day access to the conference. Additionally, you will qualify to receive CME or CE credits for the sessions you attend. Click here to register online.

When am I required to pay my conference registration?

Registration fees payments must be received on or prior to the deadline for a specific registration type (Early-Bird, Early, or Standard). If payment of a registration fee is not received by the stated deadline, the next higher category of registration fee will be applied/required to attend the conference. Prompt payment of registration fees based on the deadline schedule is encouraged.

How do I download a copy of my registration receipt?

Click here to login into your IAPAC account online. Once logged in, select “Dashboard,” then scroll to “Registrations” where you will find your conference registration if you have registered for the conference.

Where can I find the conference program?

A downloadable PDF version of the conference program is available under the “General Information” tab under the section “Conference Information”. The schedule may also be viewed by clicking the “Schedule” tab.

Is the conference accredited for CME or CE credits?

The conference will be accredited for CME and CE credits. Please review the full accreditation statement under the “General Information” tab.

Where can I find information about abstract submissions?

To learn more about online abstract submissions, including domains and general submission guidance, please click here to visit the abstracts submission portal. Note that the abstract submission deadline is February 16, 2024.

How do I submit an abstract?

Abstracts may be submitted until the deadlines outlined under the “Abstracts” tab. To submit an abstract, you will need to select the “Abstracts” tab above and scroll down to and select “Submit an Abstract”. When adding co-authors, please be sure to include their appropriate affiliation as this will be reflected in the published abstracts book if the abstract is selected for presentation. When you are ready to save or submit your abstract, select the “Update” button. Incomplete abstracts (i.e., abstracts without a track selected) will only be saved to your dashboard but not submitted to the system. Completed abstracts will automatically be submitted once the “Update” button is selected. Please regularly check your dashboard to ensure you have not made multiple submissions of the same abstract.

How do I edit an abstract I submitted?

Abstracts may be edited until the deadline outlined under the “Abstracts” tab. To access your abstract, you will need to login to your IAPAC dashboard, scroll down to “Abstract Submissions”, and select the pencil icon next to the abstract you would like to edit. When communicating with staff about your abstract, please reference your abstract ID which will begin with “CTM”. If there are abstracts under “Abstract Submissions” that you do not intend to submit for review, please delete them by selecting the garbage bin icon next to the respective abstract.

What is the word limit for abstract submissions?

Abstracts are limited to 300 words. Note, the abstract submission portal includes numbers as words, but numbers are not considered words for submission purposes. The system will alert you if you are over the word limit. If you do not receive an alert from the system, then your abstract is still within the 300 word limit and may be submitted, even if the actual word count shows as over 300.

Are there discounted hotel accommodations for conference attendees?

The conference organizers have negotiated a discounted group room rate with the venue hotel, El Conquistador, which is located in the city of Fajardo, a 35- to 40-minute commute from the San Juan International Airport (SJU). Shuttle service and other travel options to-from SJU as well as downtown San Juan will be announced shortly. Click here to reserve your accommodations at the venue hotel. We encourage early booking. Please note that the room rate for El Conquistador includes the bell man and housekeeping gratuities.

Since the host hotel is filling up quickly, we are offering additional options. Please check the “Venue” tab to view full information on available accommodations.

Are there conference scholarship opportunities for travel and accommodations?

Due to budget constraints, scholarships for travel and accommodations are not available at this time.

I am applying for my travel visa. Where can I request a letter of invitation to support my application?

Click on the following link to request your official letter of invitation for visa purposes. Continuum 2024 Invitation Letter Request Form. Note: IAPAC is unable to contact embassies or visa processing services to request assistance with visa applications. Please contact your local USA embassy or consulate general for visa-related queries.

Is there a conference app?

Yes, there will be a conference app. A QR code for the conference app will be emailed to registered delegates in June 2024.

Are there any hosted symposia or sponsorship opportunities?

There are a limited number of exhibitor spaces and sponsorship opportunities available for this conference. If you are interested, contact IAPAC Senior Director of Education Jonathon Hess at jhess@iapac.org to request a sponsorship prospectus.

I still have questions. Whom can I contact?

For registration and general conference queries: events@ftcinstitute.org

For hosted symposia and sponsorship opportunities: jhess@iapac.org

For abstract-related queries: cmoore@iapac.org

Please direct any questions about accessing the venue and accommodations directly to El Conquistador and reference the IAPAC conference: +1 787-863-1000



					

Our Conferences

Puerto Rico

June 9 - 11, 2024

Register

Paris

October 13 - 15, 2024

Register

Montréal

July 28, 2022

View Archives

Virtual

September 15 - 16, 2022

View Archives

Virtual

November 30, 2022 - December 1, 2022

View Archives

Virtual

October 2020 - March 2021

View Archives